AppLovin 3Q26 Business Update: No Notes
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
I think $HONA looks pretty attractive here. Some execution risk, but this is fundamentally a fantastic business that is experiencing short term issues, while experiencing spinoff selling and hedge fund degrossing. I think it's hard to lose too much money here.
Wonder when $META will do the same for Muse. They obviously can sustain it a lot longer than SpaceX but Muse (as Zuck noted on their call) is very expensive Have seen sell side putting around $180 / year cost estimates per user in the free tier. Not cheap https://t.co/j1RqQzdZpZ
Pretty crazy: $AAPL is now negatively correlated to $QQQ for the first time ever. The market is treating Apple as a safe haven from AI capex. https://t.co/KnzKu2Fpff
Had no $META position for the whole of September and October, but I think I'm going to be picking up some again this week. Been talking to a lot of people in advertising and I think a lot of investors really underestimate just how powerful their ads business is. Nasdaq https://t.co/4YcupLeKKu
Crazy chart that puts things into context. US bonds issued by Amazon, Alphabet, Meta, Microsoft and Oracle: 2024: <$17bn 2025: $93bn 2026 YTD: $182 BILLION 10 of the 21 largest bond deals ever were done this year. $MSFT $AMZN $GOOGL $META $ORCL https://t.co/PCO7m8heFi
Newest out. Altria: Dutiful $MO $PM $BTI $IMBBY $STG $HAYPP https://t.co/eiMmjAwcRb
@modestproposal1 Largest suppliers would be $NVDA $MRVL and memory vendors. Got to be NVDA? Maybe in connection w/ the big GPU commits
Amazon’s AWS grew 39.3% with roughly 39% margins, while retail unit growth and lower cost to serve expand its delivery network’s reach.
Intel's Q3 2026 results were hit by memory costs and an Israel shutdown, but enterprise AI inference could lift CPU demand as server…
Telkom Indonesia trades at 9x earnings and an 11% yield as MSCI-driven selling obscures telecom consolidation, price increases and…
Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…
Delta Air Lines' premium, loyalty and ancillary businesses generate 61% of revenue as cash flow supports debt reduction despite fuel and…
Microsoft rose 6.7% to a $555.80 record after Q1 FY27, with profitable growth and free cash flow reinforcing investor confidence in its AI…
GPC’s NAPA commercial sales grew 4% in Q3, trailing AutoZone and O’Reilly as freight, fuel and rent cut North American Automotive margins…
AMSC and Datadog will be fine, while SiTime is worth a closer look.
Intuit CEO Sasan Goodarzi discusses using AI to turn accountants from customer-acquisition partners into customers, alongside QuickBooks,…
DigitalOcean reported Q3 revenue up 40% to $321 million and lifted Q4 guidance above consensus, while GPU and data-center expansion cut…
Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…
L3Harris booked $19.3 billion of Q3 orders, lifting backlog to $53.2 billion, raised FY26 guidance and cut its 2028 free-cash-flow target…
Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…
David Orr describes running Militia Capital’s roughly 500-stock long-short portfolio, using expected value, correlation and factor…
Coupang expects Product Commerce margins to return to pre-data incident levels by mid-2027 as customer spending recovers and Taiwan…
Novo Nordisk beat Q3 consensus as Wegovy pill sales reached DKK 5.4bn, raised 2026 guidance again and reported DKK 79.2bn revenue.
Shopify's 3Q 2026 GMV grew 30% FX-neutral, reaching 46% of Amazon retail GMV after merchants captured nearly half of incremental U.S.
Eli Lilly uses AI-driven drug discovery and its research scale to accelerate molecule development and broaden its product pipeline.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.